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Intravenous (IV) iron and Erythropoiesis Stimulating Agents (ESAs) are recommended for anemia management in chronic kidney
disease (CKD). This retrospective cohort study analyzed utilization patterns of IV iron and ESA in patients over 18 years of
age admitted to University Health System Hospitals with a primary or secondary diagnosis of CKD between January 1, 2006
to December 31, 2008. A clustered binomial logistic regression using the GEE methodology was used to identify predictors of IV
iron utilization. Only 8% (n = 6678) of CKD patients on ESA therapy received IV iron supplementation in university hospitals.
Those receiving iron used significantly less amounts of ESAs. Patient demographics (age, race, primary payer), patient clinical
conditions (admission status, severity of illness, dialysis status), and physician specialty were identified as predictors of IV iron use
in CKD patients. Use of IV iron with ESAs was low despite recommendations from consensus guidelines. The low treatment rate
of IV iron represents a gap in treatment practices and signals an opportunity for healthcare improvement in CKD anemic patients.

1. Introduction
In the United States, Chronic kidney disease (CKD) aﬀects
approximately 26 million Americans and is the cause of
significant morbidity and mortality in 1 of 9 adults [1].
Anemia is a common comorbidity of CKD–prevalent in 47%
of patients who are not on dialysis [2]. Anemia of CKD
results from underproduction of endogenous erythropoietin
by the kidneys [3]. In patients with CKD not requiring
dialysis, untreated anemia increases cardiovascular risk,
hospitalization [4], all-cause mortality [5], and impaired
cognitive function [1], and diminishes health-related quality
of life [6] and exercise capacity [7, 8]. Heightened risk

for progression of kidney failure has also been linked to
untreated anemia of CKD. Thus, management of anemia in
CKD patients is essential [9–11].
Erythropoiesis-stimulating agents (ESAs), such as epoetin alfa (EPO) and darbepoetin, are used to treat anemia.
Use of ESAs substantially reduces the need for transfusions
and therefore are a first line of therapy for anemia of CKD
[12].
Despite their benefits, use of ESAs has inherent risks.
ESAs have been associated with increased risk of adverse
events, such as cardiovascular complications [13–16], hypertension [17], and pure red cell aplasia [18]. The US Food and
Drug Administration (FDA) added a black box warning to
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the labeling of all epoetin and darbepoetin products advising
prescribers to adjust ESA dosing to maintain the lowest
hemoglobin level needed to avoid the need for red blood
cell transfusion [19]. In addition, the FDA recently required
all ESAs be a part of the Risk Evaluation and Mitigation
Strategies (REMS) program to ensure the safe use of these
drugs [20].
Adding iron to ESA regimens may reduce the dose of
ESAs required to target Hb levels and therefore reduce the
risk of adverse events. Iron supplementation replaces iron
lost through the process of erythropoiesis stimulated by
ESAs. Indeed, the Dialysis Patients Response to IV Iron with
Elevated Ferritin (DRIVE I and II) studies showed iron supplementation with ESAs to be associated with higher Hb levels and fewer serious adverse events [21, 22]. Consequently,
the National Kidney Foundation-Kidney Disease Outcomes
Quality Initiative (NKF-KDOQI) guidelines recommend
that supplemental iron be administered intravenously in
hemodialysis dependent CKD patients [23]. Guidelines also
recommend that nondialysis-dependent CKD patients and
peritoneal dialysis dependent CKD patients receive iron
orally or intravenously [23]. Ongoing administration of
parenteral iron preserves levels of hemoglobin and reduces
the requirement for administration of erythropoietin [15, 16,
24].
There have been no studies examining recent medication
utilization patterns of IV iron in CKD patients. A single
previous investigation reported trends in IV iron use among
US Medicare dialysis patients [25]. The study reported an
increase in the use of IV iron in ESRD patients from 1997
to 2002 with ferric gluconate and iron sucrose being the
predominant form of therapy [25]. This investigation uses
more recent data to quantify the rate and extent of IV iron
and ESA utilization in anemic CKD patients resulting from
the utilization of ESA with IV iron and without IV iron.
The primary objectives of this investigation are as
follows:
(1) to quantify the rate and extent of utilization of IV iron
and ESAs in anemic CKD patients across teaching
hospitals in the US,
(2) to identify predictors of IV iron and ESA use
among the domains of patient characteristics, clinical
conditions, physician characteristics, hospital characteristics and treatment characteristics.
The authors hypothesize that IV iron supplementation
will lead to reduction in ESA use in anemic CKD patients
and that IV iron use is associated with patient characteristics, clinical conditions, physician characteristics, hospital
characteristics, and treatment characteristics of anemic CKD
patients.

2. Methods
2.1. Data. Data for this research came from the University HealthSystem Consortium (UHC) hospital database,
a member-driven alliance of approximately 90% of the
nonprofit academic medical centers in the United States.

For this study, UHC’s Clinical Resource Manager (CRM)
database was used to gather data from hospital discharge
summaries and Uniform Billing-92 data. Inpatient records
from the database provided primary and secondary diagnoses (in International Classification of Diseases, 9th Revision,
Clinical Modification [ICD-9-CM] format), inpatient procedure codes (in ICD-9-CM format), patient demographic
information (age, race, gender, primary and secondary
insurer), and hospital demographic information (bed size
and geographical location). The database also provided
admission and discharge dates as well as information on
comorbidities, severity of illness, and physician specialty.
2.2. Study Population. The data warehouse was electronically
queried for patients with Chronic Kidney Disease using ICD9-CM codes. Eligible patients were those who were admitted
to a UHC hospital with primary or secondary diagnoses of
CKD who received either IV iron or ESA or both at least
once during the period of January 1, 2006, and December
31, 2008.
2.3. Inclusion and Exclusion Criteria. Patients eligible for
inclusion had to be at least 18 years of age with primary or
secondary diagnosis of CKD. The patients in the treatment
cohort were required to have received ESA alone or ESA +
IV iron treatment during the study’s time period. Patients
with evidence of cancer diagnosis, chemotherapy or radiotherapy, blood transfusion, severe gastrointestinal bleeding,
HIV/AIDS during the observation period were excluded to
avoid including patients receiving ESA or IV iron for reasons
other than anemia of CKD. Diagnoses and procedure codes
used for inclusion and exclusion are described in Tables 1 and
2. This study was approved by the Virginia Commonwealth
University institutional review board.
2.4. Statistical Analysis. Statistical analyses were performed
using the Statistical Analysis Software (SAS v. 9.2) and the
Predictive Analytical Software (PASW v. 17.0, previously
SPSS) statistical software. A two-sided alpha of 0.05 was
considered significant.
For description of IV iron and ESA use, percentages
and chi-square values were calculated for the study sample
and subcategories. To assess the prevalence rate of usage of
ESA and IV iron from 2006 to 2008, a trend evaluation was
performed for both the drugs. Diﬀerences between the study
groups were calculated using t-tests, statistical significance
set at P < 0.05. The days of therapy (DOTs) for ESA and
IV iron therapy administered to individual patients were
determined. The mean duration of therapy for each drug
was calculated. The aggregate of drug use in each hospital for
each year was expressed as DOTs per 100 patient-days (PDs).
For example, if a patient received a single dose of a drug (ESA
or IV iron) on a given day, whether or not multiple doses are
usually administered, it was registered as 1 DOT. If a patient
received more than 1 ESA drug (epoetin or darbepoetin) on
the same day, it was counted as 1 DOT for ESA therapy.
Days of hospitalization for each patient at each hospital were
summed to provide total patient-days (PDs).
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Table 1: Diagnoses codes (ICD-9-CM) and procedure codes used to identify Chronic Kidney Disease patients (inclusion criteria).
Diagnoses and procedure codes for inclusion criteria
Diagnoses codes
Description
Chronic renal failure
Renal failure, unspecified
Renal sclerosis, unspecified
Hypertensive renal disease
Hypertensive heart and renal disease
Nephrotic syndrome
Chronic glomerulonephritis
Nephritis (NOS as acute or chronic)
Chronic pyelonephritis (without lesion of renal medullary necrosis)
Chronic pyelonephritis (with lesion of renal medullary necrosis)
Renal dialysis status
Fitting or adjustment to dialysis catheter
Adequacy testing for hemodialysis or peritoneal dialysis
Encounter for dialysis and dialysis catheter care
Anemia of Chronic kidney disease
Procedure codes
Hemodialysis
Peritoneal dialysis

ICD-9-CM Codes
585.1–585.6, 585.9
586
587
403.00–403.9
404.00–404.9
581.0–581.9
582.0–582.9
583.0–583.9
590.00
590.01
V45.1
V56.1-V56.2
V56.3, V56.31, V56.32
V56.0, V56.8
285.21
39.95
54.98

Table 2: Diagnoses codes (ICD-9-CM) and procedure codes used to identify Chronic Kidney Disease patients (exclusion criteria).
Diagnoses and procedure codes for exclusion criteria
Diagnoses codes
Description
Neoplasms
Blood transfusion
Kidney/other organ transplant
Gastrointestinal bleeding
HIV/AIDS
Procedure codes
Chemotherapy
Radiation therapy
Blood transfusion
Kidney/organ transplant
Gastrointestinal bleeding

A clustered binomial logistic regression model using the
GEE methodology was used to identify the predictors of
IV iron use. The dependent variable was drug use, and
the independent variables to be included in the model
were (1) patient characteristics (age, race, gender, length
of stay, primary payer), (2) patient clinical conditions
(admission status, severity of illness, discharge status, dialysis
status), (3) physician characteristics (physician specialty), (4)
hospital characteristics (total hospital costs). Comparisons
were considered statistically significant at P < 0.05. A
goodness of fit test (QIC and QICC) was performed to
evaluate how well the model fits the observations [26].
The goodness of fit test helped determine which of the
correlation structures was more appropriate and the best

ICD-9-CM Codes
140.00–239.00
V58.2
996.8, E878.0, V42
569.3, 578.9, 626, 627
042, V08, 795.71
00.10, 99.85, 99.25, 92.28, 99.28
14.26, 92.41, 92.25, 92.21, 92.22, 0.18, 14.27, 92.26
99.03, 38.92, 38.94, 99.02
00.91–00.93
44.43, 44.44

subset of predictors. A Huber-White sandwich estimator
(robust estimator) was used to ensure that the variances were
robust [27]. Specifically, robust variances are important as
they provide accurate assessments of the sample-to-sample
variability of the parameter estimates even if the model is
misspecified.

3. Results
3.1. Study Population. Demographic, clinical, and treatment
characteristics for the study sample for the categorical
variables are described in Tables 3, 4, and 5. The typical
patient in the total sample was a black male over 50 years
of age with an emergency admission paid for by Medicare.
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Table 3: Demographic characteristics of the study sample.

Variable

ESA + IV Iron
n = 6678

ESA alone
n = 76269

Total
N = 82947

n (%)

n (%)

N (%)

369 (5.53)
1476 (22.10)
2074 (31.06)
2759 (41.31)

4728 (6.20)
19349 (25.37)
24546 (32.18)
27647 (36.25)

5097 (6.14)
20825 (25.11)
26620 (32.09)
30406 (36.66)

3348 (50.13)
2299 (34.43)
514 (7.70)
517 (7.74)

30504 (40)
32010 (41.97)
7742 (10.15)
6013 (7.88)

33852 (40.81)
34310 (41.36)
8256 (9.95)
6530 (7.87)

3615 (54.13)
3063 (45.87)

39940 (52.37)
36330 (47.63)

43555 (52.51)
39393 (47.49)

1157 (17.33)
4588 (68.70)
710 (10.63)
97 (1.45)
126 (1.89)

11092 (14.54)
53834 (70.58)
9026 (11.83)
924 (1.21)
1394 (1.83)

12249 (14.77)
58422 (70.43)
9736 (11.74)
1021 (1.23)
1520 (1.83)

Demographic characteristics
Age group (years)∗
18–30
31–50
51–64
≥65
Race∗
White
Black
Hispanic
Other
Gender
Male
Female
Primary payer∗
Commercial/Private payer
Medicare
Medicaid
Self-pay
Other
∗ Diﬀerences

between the study groups were statistically significance at P < 0.05.

The average patient was not on dialysis, had an illness status
rated as “major,” and was discharged or transferred alive. The
typical patient was treated by an internal medicine physician,
in a hospital of more than 600 beds, and more likely to receive
epoetin as an ESA.
Of the 82,947 patients receiving ESAs, only 6,678 (8%)
received IV iron. Univariate chi-square tests indicated significant diﬀerences for all categories of demographic, clinical,
and treatment characteristics although some variables had
greater practical diﬀerences than others. One diﬀerence was
the age related-impact of IV iron use which increased with
age. Another diﬀerence was race where whites were more
likely than other racial categories to receive iron with ESAs.
Iron supplementation was more likely with epoetin than
darbepoetin, and iron sucrose was used much more often
with ESAs than iron dextran. Univariate statistical diﬀerences
in gender, primary payer, admission status, severity of illness,
discharge status, dialysis status, physician specialty, bed size,
and geographical region were present although they varied
by a few percentage points.
3.2. Trends for IV Iron and ESA Use and Days of Therapy.
Figure 1 displays the usage trends for IV iron and ESA
therapy in CKD patients over the study period. ESA use
increased from 2006 to 2007 and then decreased after the
last quarter of 2007 to 2008. In contrast, the use of IV
iron therapy in CKD patients on ESA showed a small but
steady increase over the two-year period. Comparing the two
therapeutic groups (ESA + IV iron and ESA alone), fewer

patients used IV iron along with ESA from 2006 to the second
quarter of 2007. There was a notable increase in the number
of patients using IV iron along with ESA as compared to ESA
alone from the third quarter of 2007 to 2008.
Of the individuals on IV iron, 85% (n = 5,678) received
iron sucrose and the remaining 15% (n = 1,000) received
iron dextran. Average IV iron use in CKD patients increased
sharply from 2006 to 2008 (Table 6), although it still
remained a small fraction of all CKD patients.
The days of therapy (DOTs) for ESA and IV iron therapy
administered to individual patients was determined. The
mean duration of therapy for each drug was calculated.
The aggregate of drug use for each year was expressed
as DOTs per 100 patient-days (PDs). Table 7 lists the
mean DOTs/100 PDs for IV iron and ESA therapy. The
mean (±SD) ESA DOTs/100 PDs was 12.36 ± 21.92 in
the ESA group and 8.66 ± 20.28 in the IV iron group.
t-test results showed a statistically significant mean difference of 3.7 [(95% CI = 3.15, 4.24), SE = 0.278,
P < 0.001].
Figure 2 shows change in the mean ESA DOTs/100 PDs
with each quarter of drug use from 2006–2008. There is a
significant increase in the mean ESA use in the first quarter of
2006 (P = 0.03). Notice the significant (P = 0.005) decrease
in the use of ESA from the second quarter of 2006 to the
third quarter of 2007. A substantial drop in the mean use
of ESA occurred from the third quarter of 2006 to the first
quarter of 2008 (P < 0.001). Figure 3 shows the change in the
mean IV Iron DOTs/100PDs with each quarter of drug use
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Table 4: Clinical characteristics of the study sample.

Variable
Clinical characteristics
Admission status∗
Emergency
Urgent
Elective
Other
Severity of illness∗
Moderate
Major
Extreme
Discharge status∗
Discharged/Transferred alive
Expired
Other
Dialysis status∗
On dialysis
Not on dialysis
Physician specialty∗
Internal medicine
Nephrology
Cardiology
Transplant
Pulmonary/Critical care
Hospitalist
Surgery
Bed size∗
1–399
400–599
600–799
800 or more
Geographical region∗
Midwest
Northeast
Southeast
Southwest
West
∗

ESA + IV Iron
n = 6678

ESA alone
n = 76269

Total
N = 82947

4130 (61.84)
1436 (21.50)
1017 (15.23)
95 (1.42)

44360 (58.16)
20015 (26.24)
10636 (13.95)
1259 (1.65)

48490 (58.46)
21451 (25.86)
11653 (14.05)
1354 (1.63)

817 (12.32)
3859 (57.79)
2002 (29.98)

10205 (13.38)
41673 (54.64)
24392 (31.98)

11022 (13.29)
45532 (54.89)
26394 (31.82)

6440 (96.44)
236 (3.53)
2 (0.03)

72782 (95.43)
3461 (4.54)
26 (0.03)

79222 (95.51)
3697 (4.46)
28 (0.03)

1776 (26.59)
4902 (73.41)

23546 (30.87)
52724 (69.13)

25322 (30.53)
57626 (69.47)

2182 (32.67)
1319 (19.75)
750 (11.23)
273 (4.09)
196 (2.94)
320 (4.79)
823 (12.32)

25652 (33.63)
12793 (16.77)
8141 (10.67)
3696 (4.85)
2635 (3.45)
3391 (4.45)
9260 (12.14)

27834 (33.56)
14112 (17.01)
8891 (10.72)
3969 (4.78)
2831 (3.41)
3711 (4.47)
10083 (12.16)

1728 (25.88)
1281 (19.18)
2005 (30.02)
1664 (24.92)

12309 (16.14)
22099 (28.98)
25584 (33.54)
16278 (21.34)

14037 (16.92)
23380 (28.19)
27589 (33.26)
17942 (21.63)

2416 (36.18)
1826 (27.34)
848 (12.70)
456 (6.83)
1132 (16.95)

17498 (22.94)
17045 (22.35)
17264 (22.64)
10879 (14.26)
13583 (17.81)

19914 (24.01)
18871 (22.75)
18112 (21.84)
11335 (13.67)
14715 (17.74)

Diﬀerences between the study groups were statistically significance at P < 0.05.

Table 5: Treatment characteristics of the study sample.
Variable
Treatment characteristics
ESA type∗
Epoetin
Darbepoetin
Unknown
IV iron type
Iron sucrose
Iron dextran
∗

ESA + IV Iron
n = 6678

ESA alone
n = 76269

Total
N = 82947

3428 (51.3)
2082 (31.2)
1168 (17.5)

44106 (57.8)
32163 (42.2)
0 (0)

47534 (57.3)
34245 (41.3)
1168 (1.4)

5678 (85)
1000 (15)

NA

NA

Diﬀerences between the study groups were statistically significance at P < 0.05.
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Table 6: Annual percentages of chronic kidney disease patients treated with IV iron.

Hemodialysis
Total number of patients
Iron sucrose (%)
Iron dextran (%)
Peritoneal dialysis
Total number of patients
Iron sucrose (%)
Iron dextran (%)
Not on dialysis
Total number of patients
Iron sucrose (%)
Iron dextran (%)

2006

2007

2008

395
359 (91)
36 (9)

544
514 (94)
30 (6)

779
718 (92)
61 (8)

17
10 (41)
7 (59)

18
16 (89)
2 (11)

23
19 (83)
4 (17)

1197
923 (77)
274 (23)

1516
1263 (83)
253 (17)

2189
1856 (85)
333 (15)

Table 7: Mean days of therapy/100 patient days by drug group.
Variable

Mean
8.66
30.41

ESA DOTs/100 PDs
IV Iron DOTs/100 PDs

IV Iron +ESA therapy
SD
20.28
28.20

Mean
12.36
NA

ESA therapy alone
SD
21.92
NA

P-value
<0.001
NA

IV: Intravenous.
ESA: Erythropoiesis stimulating agents.
DOTs: Days of therapy.
PDs: Patient days.

Percentage of CKD patients (N = 82.947) receiving ESA and
IV iron from 2006–2008
12
10

(%)

8
6
4
2

2008-4

2008-3

2008-2

2008-1

2007-4

2007-3

2007-2

2007-1

2006-4

2006-3

2006-2

2006-1

0

Time (quarterly)
Drug group
ESA alone
IV iron + ESA

Figure 1: Quarterly percentages of the study population receiving
ESA alone and ESA + IV iron from 2006–2008.

from 2006–2008. Note the significant increase of IV iron use
from the first quarter of 2007 to the second quarter of 2008
(P < 0.001).

3.3. Predictors of IV Iron Use. Older adults (≥65 years)
were 1.246 times more likely to be prescribed IV iron for
anemia of CKD compared to young adults in the age range
of 18–30 years [95% CI (1.108, 1.402), P < 0.001]. Race
was found to be a strong predictor of drug use in the
anemic CKD population. African Americans and Hispanics
were 0.685 [95% CI (0.647, 0.726) P < 0.001] times and
0.627 [95% CI (0.567, 0.695) P < 0.00] times as likely
to receive IV iron compared to the White population on
ESA therapy. Patients covered under the Medicaid, any
commercial/private insurance or who paid out of pocket for
insurance were 1.141 [95% CI (1.044, 1.247) P = 0.003],
1.265 [95% CI (1.178, 1.360) P < 0.001],and 1.451 [95%
CI (1.171, 1.798) P = 0.001] times more likely to receive
IV iron therapy as compared to patients covered under
Medicare.
Patient admission status, severity of illness, dialysis
status, and patient length of stay were strong predictors of
drug use in the anemic CKD population. Patients admitted
to the hospital as emergency and elective cases were 1.34
[95%CI (1.256, 1.430) P < 0.001] times and 1.307 [95%CI
(1.202, 1.421) P < 0.001] times more likely to be prescribed
IV iron as compared to patients admitted to the hospital as
urgent cases. “Extremely” sick CKD patients were less likely
to receive IV iron as compared to “moderately” sick patients.
CKD patients not on dialysis were 0.851 [95% CI (0.8, 0.907)
P < 0.001] times as likely to receive IV iron as compared to
CKD patients on dialysis.
Nephrologists were 1.216 [95% CI (1.131, 1.308) P <
0.001] times more likely to prescribe IV iron to CKD patients

Anemia
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14
13.48
13.29

13.3

13
12.75 12.74
12.39

12.29

12.2

12

11.24

11

10.91 10.92

95% CI IV iron DOT per 100 PDs

3.5
3.206

3

2.964
2.879 2.923
2.773

2.5
2.308

2

2.088

2.065
1.958 1.923

10.61

1.852

1.801

2008-4

2008-3

2008-2

2008-1

2007-4

2007-3

2007-2

Time (quarterly)

Time (quarterly)
ESA: erythropoiesis stimulating agents
DOTs: days of therapy
PDs: patient days
CI: confidence interval

2007-1

2006-4

2006-2

2008-4

2008-3

2008-2

2008-1

2007-4

2007-3

2007-2

2007-1

2006-4

2006-3

2006-2

2006-1

2006-1

1.5

10

2006-3

95% CI ESA DOT per 100 PDs

15

IV: intravenous
DOTs: days of therapy
PDs: patient days
CI: confidence interval

Figure 2: Mean ESA DOTs/100 PDs use (with 95% CI) from 2006–
2008 (by each quarter).

Figure 3: Mean IV Iron DOTs/100 PDs use (with 95% CI) from
2006–2008 (by each quarter).

already on ESA therapy, compared to internal medicine physicians. Transplant specialists and surgeons were 0.772 [95%
CI (0.664, 0.898) P = 0.001] and 0.912 [95% CI (0.836,
0.995) P = 0.03] times as likely to prescribe IV iron to CKD
patients compared to internal medicine physicians.

[30–32], its suspected inhibition of neutrophil function [33],
and increased oxidative stress leading to atheromatous [34–
36] change as well as anaphylactic and other adverse events
associated with the use of IV iron. No large prospective
clinical trials have investigated the relationship between iron
dosing and infectious morbidity or mortality. Observation
studies by Feldman et al. [37, 38] examined the eﬀect of
IV iron on mortality and hospitalization. One study of
32,566 hemodialysis patients during 1996 and 1997 found
no significant association between cumulative iron dose and
all-cause mortality. Results of this report provide cautious
support for the safe use of cumulative iron doses greater than
1000 mg during 6 months, if needed to maintain target Hb
levels in hemodialysis patients. However, some clinicians may
still be reluctant to use iron because of lingering concerns
about iron toxicity issues.
The data indicates that ESA use is decreasing and IV
iron use is increasing, although the rate of IV iron use is
still quite low. Several events could explain these trends. The
decrease in ESA use is likely due to safety concerns with
ESA use which have resulted in a black-box warning on all
ESA products instructing prescribers to use the lowest ESA
dose that gradually increases hemoglobin concentrations to
the lowest level suﬃcient to avoid the need for red blood
cell transfusion [19]. Also, the FDA recently stated that all
ESAs prescribed must be a part of the Risk Evaluation and
Mitigation Strategies (REMS) program to ensure the safe use
of these drugs [20].
The increase in iron use is likely due to the National
Kidney Foundation-Dialysis Outcomes Quality Initiative
(NKF-DOQI) of 2006 which revised the clinical practice

4. Discussion
In this inquiry, we described the utilization of IV iron
and ESA in anemic CKD patients. Of the 82,947 CKD
patients on ESA therapy, only 8% (n = 6,678) were on IV
iron supplementation. Of those 6678 patients on IV iron,
91% were prescribed iron sucrose, and the rest received
iron dextran. Almost 30% of the CKD population was on
hemodialysis (n = 25,322).
Previous investigations report varying prevalences of IV
iron usage. Bailie et al. found IV iron being prescribed to
20% of the patients with anemia of CKD [28]. This study
included patients from four academic nephrology centers
where prescribing physicians might have been more familiar
with CKD treatment guidelines. Rasu et al. reported only 3%
of CKD patients with anemia in outpatient settings of the
US were prescribed IV iron [29]. Reasons for low prevalence
of IV iron use in this investigation are unclear, particularly
because the NKF-KDOQI clinical practice guidelines for
anemia, which are repeatedly published since 1997, make
firm recommendations for optimal use of IV iron supplementation in hemodialysis patients.
Concerns regarding long-term safety of IV iron may have
had a role in such low prevalence of use. These concerns arise
from the known eﬀect of iron as a growth factor of bacteria
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guidelines for anemia of CKD. The NKF-KDOQI guidelines
recommend that a CKD patient’s hemoglobin (Hb) be
checked annually regardless of the cause or state of their
CKD [1]. In addition, the guidelines firmly recommend iron
supplementation in order to maintain adequate iron indices
that is, transferrin saturation (TSAT) and serum ferritin
levels and Hb levels.
Despite the NKF-DOQI guidelines, only 8% (n = 6678)
of CKD patients receiving ESAs got IV iron. Of that number,
most were prescribed iron sucrose. Only 9% of patients
received iron dextran—most likely because of its known risk
of causing anaphylactoid and other life-threatening adverse
reactions. No evidence of sodium ferric gluconate use was
found in this data.
The days of therapy (DOTs) for ESA and IV iron
therapy administered to individual patients was determined
to quantify utilization of IV iron and ESA use, relative to the
use of ESA alone. Although the defined daily dose (DDD)
method is recommended by the World Health Organization
to estimate drug use, important deficiencies of the defined
daily dose method compared with direct measure of the
DOTs have recently been reported [39–42]. Specifically, the
defined daily dose method is intended to estimate the DOTs
from the quantity of drug purchased by the hospital [42].
In most countries, purchase data are more readily available
than measures of the DOTs. Electronic capture of pharmacy
dispensing and administration data now makes it feasible to
measure DOTs directly. Moreover, in the UHC data, diﬀerent
hospitals have diﬀerent measurement of units (vial, mg, mcg,
mL, units, etc.), making it diﬃcult to quantify the dose
of ESA or IV iron therapy using the DDD methodology.
DDD methods will underestimate drug exposure when
the administered daily dose is reduced for a patient with
impaired bodily function or sudden adverse events. Also,
if the administered daily dosage diﬀers significantly from
the WHO-approved DDD, then DDD methodology will not
provide an accurate assessment of the number of days of
therapy. Days of therapy (DOTs) are the most common
alternative measure of drug consumption in hospitals.
A clustered binomial logistic regression using generalized
estimating equations (GEEs) was used to identify potential
predictors of IV iron use in anemic CKD patients. Older
adults (≥65 years) were significantly more likely to be
prescribed IV iron for anemia of CKD compared to young
adults in the age range of 18–30 years. This finding is consistent with the literature demonstrating a high prevalence
of IV iron use among older adults [28]. Race was found
to be a strong predictor of drug use in the anemic CKD
population. Blacks and Hispanics were significantly less likely
to receive IV iron compared to the White population on ESA
therapy. This finding is consistent with the current literature
[28, 43] and can be associated to the socioeconomic status
of these races. Patients covered under the Medicaid, any
commercial/private insurance or who paid out of pocket for
insurance, were significantly more likely to receive IV iron
therapy as compared to patients covered under Medicare.
This finding is debatable considering the ambiguity in
Medicare coverage decisions for ESRD and predialysis CKD
patients. Dialysis patients, regardless of age, have been
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entitled to Medicare coverage since 1972 [44]. As a result of
widespread coverage, Medicare serves as primary insurance
for the majority of ESRD patients after the initiation of
dialysis. Most dialysis patients below the age of 65, however,
are not eligible for Medicare benefits until the fourth month
after initiating dialysis. Medicare does not cover any costs of
treatment during these first three months of dialysis unless
the patient already has primary Medicare coverage because
of age or disability. The private health plan is the only payer
for the first three months of dialysis. When a patient becomes
eligible for Medicare due to ESRD in the fourth month of
dialysis, there is a 30-month “coordination period” when
the health plan serves as the primary payer for health care
services and Medicare becomes the secondary payer. At the
end of this 30 month period, Medicare pays for all Medicare
covered services as a primary payer, and the health plan
becomes the secondary payer [44]. Only 31% of the sample
CKD population (N = 82,947) was on dialysis, while the
majority (>60%) of patients were predialysis CKD patients
and in the age range of less than 65 years who may not be
covered by Medicare as their primary payer.
Patients admitted to the hospital as emergency and
elective cases were significantly more likely to be prescribed
IV iron as compared to patients admitted to the hospital as
urgent cases. “Extremely” sick CKD patients were less likely
to receive IV iron as compared to “moderately” sick patients.
This finding can be explained by the concerns physicians may
have regarding the use of IV iron in terminally ill patients
and toxicity issues with IV iron. These concerns arise from
the known eﬀect of iron as a growth factor of bacteria [30–
32], its suspected inhibition of neutrophil function [33],
and increased oxidative stress leading to atheromatous [34–
36] change as well as anaphylactic and other adverse events
associated with the use of IV iron. CKD patients on dialysis
were less likely to receive IV iron as compared to CKD
patients not on dialysis. However, this finding is unusual
considering that IV iron is highly recommended to CKD
patients on dialysis.
With regards to physician specialty, nephrologists were
more likely to prescribe IV iron to CKD patients already
on ESA therapy compared to internal medicine physicians;
whereas transplant specialists and surgeons were significantly
less likely to prescribe IV iron to these patients. This finding
is consistent with our hypothesis. Recent emphasis has called
for early referral of CKD patients to nephrologists, since
this approach has been demonstrated to improve patient
outcomes and result in earlier preparation for an initiation
of dialysis and prescribe the appropriate therapy as needed
[45].
Inevitably, there were limitations to this investigation.
The first limitation is the diﬀerence in hospitals with
respect to anemia and CKD management policies and
formularies/protocols that cause variations in the utilization
patterns. However, hospital level factors were used in an
attempt to control for interhospital variability while assessing
utilization. Also, a clustered analysis using the GEE methodology was used to account for nesting of patients within
hospitals to control for erroneous inferences of associations
between independent variables and drug use. In the clustered
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models, we put a restriction that patients within a hospital
are nested and correlated when compared with patients
between diﬀerent hospitals.
Adjusting for underlying severity of illness was diﬃcult
in this investigation, because there is currently no wellvalidated severity of illness score for CKD. Previous investigations have used a variety of techniques including the Stoke
Comorbidity Grade (SCG) [46], the Khan index [47], the
Davies index [48], and the Charlson comorbidity index [49].
Unlike other indices, the Davies index does not include age,
because it was specifically designed to be used in conjunction
with age as an independent covariate. Other comorbidity
indices used in studies on ESRD patients assigned diﬀerent
weights to diﬀerent comorbidities, such as the Khan or the
Charlson index, with the weights based on the impact of
comorbid diseases on survival [50]. However, the impact
of comorbid diseases on survival may be diﬀerent from
their impact on health status and resource use [50]. This
investigation used the All Patient Refined Diagnosis Related
Groups (APR-DRGss) classification system to adjust for
severity of underlying illness [51]. The APR-DRG system
is an enhancement of the DRG structure and is a good
predictor of drug utilization, hospital costs, and resource use
[52, 53].
This investigation does not assess the appropriateness
of each the patient’s iron supplementation therapy. It is
possible that each choice not to supplement ESA use with
IV iron was rational and evidence based. However, IV iron
supplementation has been linked to better patient outcomes
for CKD anemia [22].
The patient population in this study may not represent
all CKD patients in the nation. The University HealthSystem
Consortium (UHC) database used for this study is derived
from a group of university teaching hospitals providing
tertiary care. University hospitals are diﬀerent from other
hospitals because they typically perform more complex
procedures, have higher costs, and result in longer patient
length-of-stays than community hospitals.[54] Therefore,
the results of this study may not be directly extrapolated to
the general hospital community of the USA.
Finally, this study faces the same limitation seen in any
exploration of archived inpatient hospital data. Inaccurate
coding or missing data may introduce bias in the results.
Also, the database does not contain data that might be better
predictors of prescribing. We were unable to assess physicians’ prescribing intent or their knowledge of recommended
guidelines. In addition, we could not assess pharmaceutical
industry influence or laboratory values such as hemoglobin,
transferrin saturation, serum ferritin, and other iron indices
which may be possible predictors of IV iron use in anemic
CKD patients.

5. Conclusion
This inquiry describes the utilization of IV iron and ESA
in anemic CKD patients, with a focus on understanding
predictors of drug use. Data collected from 62 teaching
hospitals between 2006 and 2008 showed an increasing trend
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in the use of IV iron in anemic CKD patients already on
ESA therapy. Use of IV iron supplementation was associated
with a significant decrease in the duration of therapy of ESA.
Despite this positive finding for supplementing ESA administration with IV iron, only 8% of CKD patients receiving
ESAs also received IV iron. Patient demographics (age, race,
primary payer), patient clinical conditions (admission status,
severity of illness, dialysis status), and physician specialty
were identified as predictors of IV iron use in CKD patients.
Use rates of IV iron in this population suggest that
anemia management therapies may be underutilized in
CKD anemic patients in spite of emphasis on the use of
IV iron in the consensus guidelines. The low treatment
rate represents a gap in treatment practices and signals
an opportunity for healthcare improvement. Pathologic
factors, physician practice patterns, pharmaceutical industry
influence aﬀecting rates of IV iron use in anemia of CKD,
along with patient-centered clinical and economic outcomes
of such treatment merit further research.
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